

**Ohio Department of Job and Family Services (ODJFS)**  
**Drug Utilization Review (DUR) Board**  
**Quarterly Meeting**  
**February 24th, 2010**

The quarterly meeting of the ODJFS DUR Board was called to order at 12:10 PM in room 1948 of the Riffe Building, 77 S. High St. Columbus, Ohio. Kevin Mitchell, RPh, presided. The following Board members were present:

David Brookover, RPh  
J. Layne Moore, MD  
Lenard Presutti, DO

Also present were Margaret Scott, RPh, DUR Administrator, Jill Griffith, RPh, DUR Director, and from the University of Cincinnati College of Pharmacy, Pam Heaton RPh, PhD and Bob Cluxton, RPh, PhD. Michael Farrell, MD, Thomas Gretter, MD, Robert Kubasak, RPh, and Donald Sullivan, PhD, RPh, were absent. Approximately 15 observers were present, most representing pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The November 18<sup>th</sup>, 2009, DUR Board minutes were approved with one correction. Dr. Presutti was listed as MD instead of DO. (1<sup>st</sup> D. Brookover, 2<sup>nd</sup> L. Presutti).

DUR Committee Report:

J. Griffith gave the DUR Committee report.

The December 2009 DUR Committee re-reviewed the use of ODT formulation antipsychotics and antidepressants in patients able to swallow other tablet formulations. 146 letters were mailed in December 2008. 141 patients were available for re-review in December 2009. 43% were switched from an ODT formulation to a regular tablet while 53% continued on ODT therapy. Five patients were lost to follow up.

The January 2010 DUR Committee re-reviewed three topics: use of liquid antidepressants in patients able to swallow tablet formulations, duplicative inhaler use, and use of the thiazolidinediones (TZDs) in patients with congestive heart failure (CHF). 66 liquid antidepressant letters were mailed in January 2009. 46% of patients were switched to a tablet formulation. 36% continued on the liquid formulation and 18% were lost to follow up. The duplicative inhaler re-review found that of the 105 letters mailed in February 2009, 59% of patients discontinued use of the duplicative inhaler, 16% did not show any changes in care and 25% were lost to follow up. Regarding TZD use in patients with a diagnosis of CHF, 186 letters were mailed in March 2009. 171 profiles

were available for re-review in January 2010. 39% of patients had been counseled by their healthcare provider regarding the signs and symptoms of heart failure or had their TZD discontinued. 37% showed no change in care, 9% of patients did not have a diagnosis of CHF and 15% were lost to follow up.

The February DUR committee meeting was a quality assurance meeting to review the year and discuss ways to improve the DUR program.

Health Plan Policy:

M. Scott announced that on February 1, 2010 all Ohio Medicaid consumers moved to the fee-for-service pharmacy program, meaning that all consumers have one list of covered drugs and prior authorization policy. Some medical supplies such as diabetic testing supplies, supplies for self-injection of medication, inhaler spacers and peak flow meters are now covered by the pharmacy benefit. ODJFS anticipates saving \$235 million dollars in state fiscal year 2011.

Unfinished Business:

Letters for the ophthalmic and otic quinolones and proton pump inhibitor reviews were approved.

New Business:

M. Scott asked Board members to sign the conflict of interest form.

Announcements:

The next DUR Board meeting will be at noon on Wednesday, May 19th. Locations to be determined. Meeting dates for September and November 2010 will be decided at the May meeting.

Adjournment:

K. Mitchell adjourned the meeting at 12:20 PM.

Respectfully submitted:

---

Jill R.K. Griffith B.S., Pharm.D., DUR Program Director